Clinical outcomes of switching to adalimumab biosimilar (MSB11022) in patients with rheumatoid arthritis: RESTART Spanish Registry-Reference-Cited by-同舟云学术

Clinical outcomes of switching to adalimumab biosimilar (MSB11022) in patients with rheumatoid arthritis: RESTART Spanish Registry

Published:2024-07-04 Issue:8 Volume:40 Page:1431-1438
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

García-Miguel Javier¹,Yankova Komsalova Liliya²,Mata Arnaiz Cristina³,Alegre-Sancho Juan José⁴,González Polo Javier⁵,Torrente-Segarra Vicenç⁶,Tornero Molina Jesús⁷,Navarro Angeles Vanessa Andrea⁸,Caramés Cristina⁹,Cristóbal Ion⁹

Affiliation:

1. Servicio de Reumatología, Hospital Universitari Sagrat Cor de Barcelona, Barcelona, Spain

2. Servicio de Reumatología, Hospital Marina Salud, Denia, Alicante, Spain

3. Servicio de Reumatología, Hospital Comarcal de Laredo, Laredo, Cantabria, Spain

4. Servicio de Reumatología, Hospital Universitario Dr. Peset, Valencia, Spain

5. Servicio de Reumatología, Hospital nuestra Señora del Prado, Talavera de la Reina, Spain

6. Servei de Reumatologia, Consorci Sanitari Alt Penedès Garraf, Barcelona, Spain

7. Servicio de Reumatología, Hospital Universitario de Guadalajara, Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá de Henares, Madrid, Spain

8. Servicio de Reumatología, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain

9. Departamento Corporativo de Investigación e Innovación, Dirección Corporativa Asistencial y de Investigación, Quirónsalud, Madrid, Spain

Funder

Fresenius Kabi

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2372295

Reference30 articles.

1. Management of Rheumatoid Arthritis: An Overview

2. Spanish Society of Reumatology. Clinical practice guidelines for the management of patients with rheumatoid arthritis [cited 2024 April 19]. Available at https://www.ser.es/wp-content/uploads/2020/04/Clinical-Practice-Guidelines-for-the-Management-of-Patients-with-Rheumatoid-Arthritis.pdf.

3. US Food and Drug Administration. Summary of product characteristics: Humira® (adalimumab). [April 19]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf.

4. European Medicines Agency. Summary of Products Characteristics: humira® (adalimumab). [cited 2024 April 19]. Available at https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf.

5. Overview of Humira® Biosimilars: Current European Landscape and Future Implications